{"nctId":"NCT03559062","briefTitle":"A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis","startDateStruct":{"date":"2018-05-17","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":67,"armGroups":[{"label":"Placebo","type":"OTHER","interventionNames":["Drug: Placebo"]},{"label":"TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: TEZ/IVA","Drug: IVA","Drug: Placebo"]},{"label":"Ivacaftor","type":"EXPERIMENTAL","interventionNames":["Drug: IVA","Drug: Placebo"]}],"interventions":[{"name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor fixed dose combination"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in the protocol).\n* Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.\n* Participants with a screening LCI2.5 result ≥7.5.\n* Participants who are able to swallow tablets.\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension.\n* Colonization with organisms associated with a more rapid decline in pulmonary status.\n* Solid organ or hematological transplantation.\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8","description":"LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride At Week 8","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.3","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Safety Follow-up Visit","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Cough","Headache","Productive cough","Nasopharyngitis","Infective pulmonary exacerbation of cystic fibrosis"]}}}